Table 4

Association between characteristics of trials and statistically significant outcome or conclusions favoring the test drug: Multivariate logistic regression (first/main reports only, n = 115)

Results Favor Test Drug

Conclusions Favor Test Drug


Characteristic

Category

Favorable n/Total n (%)

OR

(95% CI)

P

Favorable n/Total n (%)

OR

(95% CI)

P


Trial registration before publication

No

34/70 (49)

1.00

46/70 (66)

1.00


Yes

28/45 (62)

1.11 (0.44-2.80)

0.832

34/45 (76)

1.10 (0.41-2.98)

0.854



Blinding

Stringent

13/31 (42)

1.00

20/31 (65)

1.00


Not stringent

49/84 (58)

3.03 (1.13-8.16)

0.028

60/84 (71)

1.86 (0.69-5.05)

0.221



Sample size

Natural log

-

2.20 (1.40-3.45)

<0.001

-

1.65 (1.09-2.51)

0.019



Comparison group

Active comparator

24/51 (47)

1.00

33/51 (65)

1.00


Placebo

38/64 (59)

2.33 (0.89-6.07)

0.084

47/64 (73)

1.98 (0.73-5.41)

0.182



Primary efficacy outcome

Survival

14/25 (56)

1.00

17/25 (68)

1.00


Surrogate

48/90 (53)

2.76 (0.82-9.28)

0.102

63/90 (70)

2.86 (0.80-10.18)

0.105



Sponsored

No

13/27 (48)

1.00

15/27 (56)

1.00


Yes

49/88 (56)

1.02 (0.37-2.84)

0.965

65/88 (74)

1.94 (0.71-5.29)

0.194


Rasmussen et al. Trials 2009 10:116   doi:10.1186/1745-6215-10-116

Open Data